Hepatology International

Home
India
New Delhi
Hepatology International

Hepatology International is a peer-reviewed journal dedicated to research and patient care issues.

Account is owned and managed by the society and not by Springer Nature. Hepatology International is a peer-reviewed journal dedicated to research and patient care issues in hepatology. Focuses on contemporary clinical and basic science related issues in adult and pediatric hepatobiliary and allied sciences. Publishes original research articles, editorials, reviews, and consensus guidelines for diagnosis and treatment of liver diseases. Emphasizes on new and emerging technologies, innovations and future trends in liver and biliary disorders.

24/11/2025

Explore new insights into the relationship between hepatic immune-related adverse events (irAEs) and patient outcomes in cancer therapy. This study reveals that the development of hepatic irAEs is associated with improved overall survival in patients with malignancies treated with immune checkpoint inhibitors, offering valuable implications for clinical management and monitoring.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10825-3

22/11/2025

Join us at APASL STC Pakistan 2025! 🇵🇰
📅 5–7 December 2025
📍 Karachi, Pakistan

Centered on the theme “MAFLD and Metabolic Complications: Applying Multidisciplinary Solutions,” this landmark conference unites leading experts across hepatology, endocrinology, cardiometabolic medicine, internal medicine, family medicine, nephrology, oncology, nutrition, and bariatric care.

The scientific program delves into the evolving landscape of metabolic liver disease, with sessions covering epidemiology, systemic complications, diagnostic pathways, non-invasive tools, incretin-based and emerging therapies, precision medicine, post-transplant considerations, and digital health applications — all tailored to LMIC contexts.

🔗 For more information and registration: www.apaslstc2025pakistan.com

20/11/2025

Discover the power of machine learning in predicting rapid HBsAg seroclearance at week 24 among inactive hepatitis B carriers treated with pegylated interferon. This innovative study demonstrates how AI-driven models can enhance clinical decision-making and personalize therapy in HBV management.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10936-x

18/11/2025

A prospective multicenter cohort study reveals that acute kidney injury (AKI) stage 1a significantly increases mortality in patients with cirrhosis. This important research underscores the prognostic impact of early AKI and highlights the need for timely recognition and intervention in cirrhotic patients.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10790-x

17/11/2025

Explore the latest research on the combination of ropeginterferon alfa-2b with anti-PD1 blockade as adjuvant therapy in HBV-related hepatocellular carcinoma (HCC). This study provides important insights into the potential synergistic effects of immunomodulation and checkpoint inhibition in improving post-operative outcomes.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10954-9

14/11/2025

Explore the latest review on combination therapies for chronic hepatitis B in the era of emerging novel antiviral agents. This article provides a comprehensive overview of evolving therapeutic strategies aimed at achieving a functional cure and improving long-term patient outcomes.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10888-2

28/10/2025

Explore the latest research on “Plasma exchange improves survival with native liver in Wilson disease with new Wilson’s index ≥ 11 and early hepatic encephalopathy.”

This important study highlights the clinical value of plasma exchange in improving outcomes and survival among patients with severe Wilson disease, providing new insights for optimizing management strategies.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10821-7

13/10/2025

🌍 Join us for the 35th Annual Meeting of APASL — Istanbul 2026! 🇹🇷

📅 April 22–25, 2026
📍 İstanbul Lütfi Kırdar International Convention and Exhibition Centre

Experience a landmark gathering that brings together leading experts, clinicians, and researchers from around the world to discuss the latest breakthroughs and innovations in liver disease and hepatology.

We look forward to welcoming you to Istanbul — where world-class science meets rich culture and collaboration.

🔗 For more information and registration: www.apasl2026istanbul.org

10/10/2025

Understanding the stage-specific impact of portal hypertension is crucial in optimizing surgical outcomes for hepatocellular carcinoma (HCC).

This study provides valuable insights into how portal hypertension influences prognosis and postoperative outcomes following liver resection, emphasizing the importance of individualized treatment strategies.

Read the full article here:
🔗 https://link.springer.com/article/10.1007/s12072-025-10879-3

09/10/2025

Can therapeutic vaccines transform the landscape of hepatitis B treatment? This comprehensive review explores the current advancements, challenges, and future potential of vaccine-based immunotherapies aimed at achieving a functional cure for chronic HBV infection.

Read the full article to understand how emerging vaccine strategies are reshaping the future of HBV management.

🔗 https://link.springer.com/article/10.1007/s12072-025-10907-2

08/10/2025

Emerging data from the Paracelsus 10,000 Study reveal a significant association between depression and metabolic dysfunction-associated steatotic liver disease (MASLD), underscoring the complex interplay between mental health and metabolic liver disease.

This cross-sectional analysis emphasizes the importance of integrated care approaches in managing patients with MASLD and related comorbidities.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10922-3

06/10/2025

The B-Together study explores the potential of bepirovirsen in modulating immune responses to enhance the clearance of HBV-infected hepatocytes. This research highlights a promising step toward achieving a functional cure for chronic hepatitis B through targeted immunomodulation.

🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10917-0

Address

D-1, Vasant Kunj
New Delhi

Website

https://link.springer.com/journal/12072

Alerts

Be the first to know and let us send you an email when Hepatology International posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in New Delhi?